LIMBITROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).
Limbitrol is a combination of chlordiazepoxide (a benzodiazepine) and amitriptyline (a tricyclic antidepressant). Chlordiazepoxide enhances GABA-A receptor activity, producing anxiolytic and sedative effects. Amitriptyline inhibits serotonin and norepinephrine reuptake, elevating mood and reducing pain. The combination is used for depression with anxiety.
| Metabolism | Chlordiazepoxide: Hepatic via CYP3A4, active metabolite (nordiazepam), long half-life. Amitriptyline: Hepatic via CYP2D6, CYP3A4, CYP2C19; active metabolite (nortriptyline). |
| Excretion | Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged). |
| Half-life | Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide). |
| Protein binding | Amitriptyline: 85-95% bound (primarily to α1-acid glycoprotein and albumin); chlordiazepoxide: 96-98% bound (predominantly to albumin). |
| Volume of Distribution | Amitriptyline: 15-18 L/kg (Vd ~1–2 L/kg for amitriptyline, but high tissue binding leads to large apparent Vd); chlordiazepoxide: 0.3-0.5 L/kg. Clinical meaning: extensive tissue distribution, large reservoir in peripheral compartments. |
| Bioavailability | Oral: 40-60% for amitriptyline (first-pass metabolism reduces bioavailability; range 30-70%); chlordiazepoxide: 100% (well absorbed with minimal first-pass effect). |
| Onset of Action | Oral: 30-60 minutes for initial sedative and anxiolytic effects; antidepressant effects require 2-4 weeks of continuous dosing. |
| Duration of Action | Sedative/anxiolytic effects last 4-8 hours after a single oral dose; antidepressant effects persist with chronic dosing; half-life supports once-daily dosing for maintenance. |
| Molecular Weight | Amitriptyline: 313.86 Da; Chlordiazepoxide: 299.75 Da |
1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.
| Dosage form | TABLET |
| Renal impairment | eGFR <10 mL/min: Avoid use. eGFR 10-30 mL/min: Reduce dose by 50% and monitor for toxicity. eGFR >30 mL/min: No adjustment needed. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use. |
| Pediatric use | Not recommended for use in children under 12 years. Weight-based dosing not established; consider adult-like dosing with caution in adolescents over 12 years. |
| Geriatric use | Initial dose: 1 tablet (5 mg chlordiazepoxide / 12.5 mg amitriptyline) orally once daily, increase slowly. Maximum 4 tablets per day. Avoid in elderly due to increased risk of sedation, falls, and cognitive impairment. |
| 1st trimester | Avoid: Risk of teratogenicity (neural tube defects, cardiovascular malformations) in first trimester. Amitriptyline and chlordiazepoxide have demonstrated teratogenic effects in animal studies and human data suggest increased risk of congenital malformations including oral clefts. |
| 2nd trimester | Avoid: Potential for fetal adverse effects including growth restriction and neurobehavioral alterations. Prolonged use may lead to neonatal withdrawal syndrome. |
| 3rd trimester | Avoid: Third trimester use carries risk of neonatal withdrawal (irritability, hypertonia, feeding difficulties) and respiratory depression (from chlordiazepoxide). Use only if clearly needed with careful monitoring. |
Clinical note
Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).
| Placental transfer | Both components cross the placenta. Amitriptyline exhibits moderate placental transfer with fetal-to-maternal ratio approximately 0.8. Chlordiazepoxide and its active metabolite desmethylchlordiazepoxide readily cross the placenta, achieving fetal concentrations similar to maternal. |
■ FDA Black Box Warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in short-term studies in children, adolescents, and young adults. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
Hypersensitivity to benzodiazepines or tricyclic antidepressantsAcute narrow-angle glaucomaConcurrent use of MAO inhibitors or within 14 days of discontinuationMyocardial infarction acute recovery phaseBreastfeeding (relative, but often considered absolute due to risks)Pregnancy (especially first trimester) unless absolutely necessary
| Precautions | Risk of suicidal thoughts and behaviors, Activation of mania/hypomania, Seizure threshold lowering, Cardiotoxicity (QT prolongation, arrhythmias) especially in overdose, Sedation and cognitive impairment, caution with driving, Potential for abuse and dependence (benzodiazepine component), Anticholinergic effects (dry mouth, constipation, blurred vision), Hepatic impairment may require dose adjustment |
| Food/Dietary | Avoid alcohol and grapefruit juice. Grapefruit inhibits CYP3A4, potentially increasing chlordiazepoxide levels. Alcohol potentiates CNS depression. No other significant food interactions reported. |
Loading safety data…
| Breastfeeding |
| Both amitriptyline and chlordiazepoxide are excreted into breast milk. Amitriptyline levels are low but chlordiazepoxide may accumulate in infants due to long half-life. Sedation, poor feeding, and weight loss have been reported. Not recommended, especially with preterm or compromised infants. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. Avoid use. Second trimester: Possible fetal growth restriction and preterm birth. Third trimester: Risk of neonatal withdrawal syndrome and respiratory depression at delivery. |
| Fetal Monitoring | Maternal: Serial drug levels if clinically indicated; monitor for CNS depression, weight gain, and electrolyte disturbances. Fetal: Regular ultrasound for growth and anomaly detection; nonstress test and biophysical profile in third trimester. |
| Fertility Effects | May impair female fertility through hormonal disruption; case reports of reversible spermatogenesis suppression in males. Clinical significance not fully established. |
| Clinical Pearls | LIMBITROL is a fixed-dose combination of chlordiazepoxide and amitriptyline. Chlordiazepoxide is a benzodiazepine with anxiolytic and sedative properties; amitriptyline is a tricyclic antidepressant (TCA) with anticholinergic and sedative effects. Use is limited due to drug interaction risks, additive CNS depression, anticholinergic side effects (constipation, urinary retention, blurry vision), and potential for dependence with the benzodiazepine component. Avoid in patients with narrow-angle glaucoma, urinary retention, MAOI use within 14 days, or during acute recovery phase of myocardial infarction. May cause QT prolongation; monitor ECG in elderly or those with cardiac disease. Discontinue gradually to avoid withdrawal from benzodiazepine. Contraindicated with concurrent use of CYP450 inhibitors (e.g., cimetidine, fluoxetine) which increase levels of both components. |
| Patient Advice | Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase drowsiness and risk of overdose. · Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness, drowsiness, or blurred vision. · Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor due to risk of withdrawal or rebound anxiety. · May cause dry mouth, constipation, or difficulty urinating; increase fluid intake and fiber, and report severe symptoms to your doctor. · Inform all healthcare providers you are taking LIMBITROL, especially before surgery or adding new medications. · Avoid grapefruit juice as it may increase side effects by affecting drug metabolism. · Store at room temperature away from moisture and heat; keep out of reach of children. · If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double dose. |